US
US Bacteriophage Therapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $30.2 Mn.
Canada at 14.8% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$58.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $26.8 Mn | — | — |
| 2025 (base) | $30.2 Mn | +$3.4 Mn | — |
| 2026 (forecast) | $34.1 Mn | +$3.8 Mn | +12.7% |
| 2027 (forecast) | $38.4 Mn | +$4.3 Mn | +27% |
| 2028 (forecast) | $43.3 Mn | +$4.9 Mn | +43.1% |
| 2029 (forecast) | $48.8 Mn | +$5.5 Mn | +61.3% |
| 2030 (forecast) | $55.0 Mn | +$6.2 Mn | +81.8% |
| 2031 (forecast) | $61.9 Mn | +$7.0 Mn | +104.9% |
| 2032 (forecast) | $69.8 Mn | +$7.9 Mn | +130.9% |
| 2033 (forecast) | $78.7 Mn | +$8.9 Mn | +160.3% |
| 2034 (forecast) | $88.7 Mn | +$10.0 Mn | +193.3% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$30.2 Mn
China
$6.5 Mn
Canada
$6.2 Mn
Japan
$4.6 Mn
Germany
$2.9 Mn
UK
$2.2 Mn
Brazil
$2.1 Mn
France
$2.1 Mn
Italy
$1.7 Mn
Ecuador
$1.6 Mn
India
$1.5 Mn
Saudi Arabia
$1.4 Mn
Spain
$1.3 Mn
Mexico
$1.2 Mn
Australia
$0.9 Mn
New Zealand
$0.8 Mn
Russia
$0.8 Mn
South Africa
$0.5 Mn
UAE
$0.4 Mn
Egypt
$0.1 Mn
Hong Kong
$0.1 Mn
Malaysia
$0.1 Mn
Philippines
$0.1 Mn
Singapore
$0.1 Mn
Thailand
$0.1 Mn
Kenya
$0.0 Mn
Bacteriophage therapy uses viruses that infect only bacteria to treat infections that antibiotics cannot clear.
Key segments of the bacteriophage Therapy market include type (Natural Phages, Engineered Phages and Phage Cocktails) and application (Chronic Wounds, Respiratory Infections and Urinary Infections).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the bacteriophage Therapy market.
New vaccines, rapid tests and public-private funding for neglected diseases give the bacteriophage Therapy market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the bacteriophage Therapy market.
The bacteriophage Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for bacteriophage Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Bacteriophage Therapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 1 shared keyword
US
US
US
US
US
Medical Devices · US
Medical Devices · US
OTC & Nutraceuticals · US
OTC & Nutraceuticals · US
Medical Devices · US
Healthcare Services · US